Please assess the completion status of the following clinical trial:

Trial Title: Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients can be receive drug treatment within 24 hours after stroke onset~2. Patients with a level of consciousness between 0 (alert) and 3 (unable to recall name and date of birth) according to the Japan Coma Scale~3. Patients with motor dysfunction of upper and/or lower extremities~4. Patients aged 20 years or older when giving informed consent~Exclusion Criteria:~1. Serum creatinine of \>1.5 mg/dL~2. Embolic infarction~3. Intracranial haemorrhage~4. Large infarction with severe consciousness~5. Transient ischemic attack (TIA)~6. A modified Rankin Scale score of ≥2 before stroke onset~7. Patients were receive drug treatment (argatroban, urokinase, tissue plasminogen activator, heparin, warfarin sodium, aspirin, ticlopidine hydrochloride, cilostazol, edaravone and sodium ozagrel) after stroke onset~8. Patients were receive surgical treatment or intravascular treatment~9. With severe complications (cirrhosis, heart failure, etc.)~10. Treating malignant tumor~11. Pregnant or possibly pregnant women, nursing mothers~12. History of edaravone, sodium ozagrel and ozagrel hydrochloride sensitivity~13. Less than 3 months since any other clinical trial or postmarketing study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edaravone (Type: EXPERIMENTAL): None
- Ozagrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).